S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines

Ikegaki,Naohiko; Hicks,Sakeenah   L.; Regan,Paul   L.; Jacobs,Joshua; Jumbo,Amina  S.; Leonhardt,Payton; Rappaport,Eric  F.; Tang,Xao   X.

doi:10.3892/ijo.2013.2148

S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines

Authors:
- Naohiko Ikegaki
- Sakeenah L. Hicks
- Paul L. Regan
- Joshua Jacobs
- Amina S. Jumbo
- Payton Leonhardt
- Eric F. Rappaport
- Xao X. Tang
View Affiliations

Affiliations: Department of Anatomy and Cell Biology, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA, Nucleic Acid PCR Core, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
Published online on: October 25, 2013 https://doi.org/10.3892/ijo.2013.2148
Pages: 35-43
Copyright: © Ikegaki et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuroblastoma is a common pediatric solid tumor that exhibits a striking clinical bipolarity: favorable and unfavorable. The survival rate of children with unfavorable neuroblastoma remains low among all childhood cancers. MYCN and MYC play a crucial role in determining the malignancy of unfavorable neuroblastomas, whereas high-level expression of the favorable neuroblastoma genes is associated with a good disease outcome and confers growth suppression of neuroblastoma cells. A small fraction of neuroblastomas harbors TP53 mutations at diagnosis, but a higher proportion of the relapse cases acquire TP53 mutations. In this study, we investigated the effect of S(+)-ibuprofen on neuroblastoma cell lines, focusing on the expression of the MYCN, MYC, AKT, p53 proteins and the favorable neuroblastoma genes in vitro as biomarkers of malignancy. Treatment of neuroblastoma cell lines with S(+)-ibuprofen resulted in a significant growth suppression. This growth effect was accompanied by a marked decrease in the expression of MYC, MYCN, AKT and an increase in p53 expression in neuroblastoma cell lines without TP53 mutation. In addition, S(+)-ibuprofen enhanced the expression of some favorable neuroblastoma genes (EPHB6, CD44) and genes involved in growth suppression and differentiation (EGR1, EPHA2, NRG1 and SEL1L). Gene expression profile and Ingenuity pathway analyses using TP53-mutated SKNAS cells further revealed that S(+)-ibuprofen suppressed molecular pathways associated with cell growth and conversely enhanced those of cell cycle arrest and the unfolded protein response. Collectively, these results suggest that S(+)-ibuprofen or its related compounds may have the potential for therapeutic and/or palliative use for unfavorable neuroblastoma.

View Figures

View References

1.	Cohn SL, Pearson AD, London WB, et al: The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 27:289–297. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Tang XX, Zhao H, Robinson ME, et al: Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc Natl Acad Sci USA. 97:10936–10941. 2000. View Article : Google Scholar : PubMed/NCBI
3.	Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 313:1111–1116. 1985. View Article : Google Scholar : PubMed/NCBI
4.	Brodeur GM, Seeger RC, Schwab M, Varmus HE and Bishop JM: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 224:1121–1124. 1984. View Article : Google Scholar : PubMed/NCBI
5.	Williams CS, Mann M and DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 18:7908–7916. 1999. View Article : Google Scholar : PubMed/NCBI
6.	Johnsen JI, Lindskog M, Ponthan F, et al: Cyclooxygenase-2 is expressed in neuroblastoma, and non-steroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res. 64:7210–7215. 2004. View Article : Google Scholar : PubMed/NCBI
7.	Choi SY, Choi BH, Suh BC, et al: Potentiation of PGE(2)-mediated cAMP production during neuronal differentiation of human neuroblastoma SK-N-BE(2)C cells. J Neurochem. 79:303–310. 2001. View Article : Google Scholar : PubMed/NCBI
8.	Torres J, Regan PL, Edo R, et al: Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas. Int J Oncol. 37:983–991. 2010.PubMed/NCBI
9.	Regan PL, Jacobs J, Wang G, et al: Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma. Int J Oncol. 38:105–112. 2011.PubMed/NCBI
10.	Dombroski BA, Nayak RR, Ewens KG, Ankener W, Cheung VG and Spielman RS: Gene expression and genetic variation in response to endoplasmic reticulum stress in human cells. Am J Hum Genet. 86:719–729. 2010. View Article : Google Scholar : PubMed/NCBI
11.	Tweddle DA, Malcolm AJ, Bown N, Pearson AD and Lunec J: Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res. 61:8–13. 2001.PubMed/NCBI
12.	Goldschneider D, Horvilleur E, Plassa LF, et al: Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res. 34:5603–5612. 2006. View Article : Google Scholar : PubMed/NCBI
13.	Tang XX, Evans AE, Zhao H, et al: High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas. Clin Cancer Res. 5:1491–1496. 1999.
14.	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F and Spencer F: A model-vased background adjustment for oligonucleotide expression arrays. J Am Statist Assoc. 99:909–917. 2004. View Article : Google Scholar
16.	Khwaja F, Allen J, Lynch J, Andrews P and Djakiew D: Ibuprofen inhibits survival of bladder cancer cells by induced expression of the p75^NTRtumor suppressor protein. Cancer Res. 64:6207–6213. 2004. View Article : Google Scholar : PubMed/NCBI
17.	Quann EJ, Khwaja F, Zavitz KH and Djakiew D: The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 67:3254–3262. 2007. View Article : Google Scholar : PubMed/NCBI
18.	Kung B, Zhao H, Hicks SL, Tang XX and Ikegaki N: Biological significance of EPHA2 expression in neuroblastoma. Int J Oncol. 35:845–850. 2009.PubMed/NCBI
19.	Ikegaki N, Shimada H, Fox AM, et al: Transient treatment with epigenetic modifiers yields stable neuroblastoma stem cells resembling aggressive large-cell neuroblastomas. Proc Natl Acad Sci USA. 110:6097–6102. 2013. View Article : Google Scholar
20.	Phleps W: Overview on clinical data of dexibuprofen. Clin Rheumatol. 20(Suppl 1): S15–S21. 2001. View Article : Google Scholar : PubMed/NCBI
21.	Fredlund E, Ringner M, Maris JM and Pahlman S: High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci USA. 105:14094–14099. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Tang XX, Zhao H, Kung B, et al: The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res. 66:2826–2833. 2006. View Article : Google Scholar : PubMed/NCBI
23.	Wang LL, Suganuma R, Tovar JP, et al: Neuroblastoma, undifferentiated subtype: a report from the Children’s Oncology Group. Pediatric Dev Pathol. (In press).
24.	Tang XX, Robinson ME, Riceberg JS, et al: Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma. Clin Cancer Res. 10:5837–5844. 2004. View Article : Google Scholar : PubMed/NCBI
25.	Dudek H, Datta SR, Franke TF, et al: Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 275:661–665. 1997. View Article : Google Scholar : PubMed/NCBI
26.	Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, et al: Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 385:544–548. 1997. View Article : Google Scholar : PubMed/NCBI
27.	Zong WX, Li C, Hatzivassiliou G, et al: Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis. J Cell Biol. 162:59–69. 2003. View Article : Google Scholar : PubMed/NCBI
28.	Scorrano L, Oakes SA, Opferman JT, et al: BAX and BAK regulation of endoplasmic reticulum Ca²⁺: a control point for apoptosis. Science. 300:135–139. 2003. View Article : Google Scholar : PubMed/NCBI
29.	Conacci-Sorrell M, Ngouenet C and Eisenman RN: Myc-nick: a cytoplasmic cleavage product of Myc that promotes alpha-tubulin acetylation and cell differentiation. Cell. 142:480–493. 2010. View Article : Google Scholar : PubMed/NCBI
30.	Conacci-Sorrell M and Eisenman RN: Post-translational control of Myc function during differentiation. Cell Cycle. 10:604–610. 2011. View Article : Google Scholar : PubMed/NCBI
31.	Tsutsumi S, Gotoh T, Tomisato W, et al: Endoplasmic reticulum stress response is involved in non-steroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ. 11:1009–1016. 2004. View Article : Google Scholar : PubMed/NCBI
32.	Shan J, Fu L, Balasubramanian MN, Anthony T and Kilberg MS: ATF4-dependent regulation of the JMJD3 gene during amino acid deprivation can be rescued in Atf4-deficient cells by inhibition of deacetylation. J Biol Chem. 287:36393–36403. 2012. View Article : Google Scholar : PubMed/NCBI
33.	Ikegaki N, Bukovsky J and Kennett RH: Identification and characterization of the NMYC gene product in human neuroblastoma cells by monoclonal antibodies with defined specificities. Proc Natl Acad Sci USA. 83:5929–5933. 1986. View Article : Google Scholar : PubMed/NCBI